In the online “early view” section of the journal Cancer there is a new research article proposing that using three currently-used immunohistochemical breast markers in a group of patients who received neoadjuvant chemotherapy, doctors can sub-type cancers similar to those described by molecular profiling.  They also suggest these sub-types are associated with different responses to treatment and overall survival. [...]

Many patients ask how they know if they are getting the appropriate treatment for their breast cancer. No two patients are alike and therefore treatment decisions are based upon your unique situation and the type of cancer you have. This is one reason why it is important to get a second opinion on your pathology [...]

A recent study from MD Anderson Cancer Center looked at a group of women with breast cancers that tested positive for HER2 over-expression who received neoadjuvant chemotherapy.  Of the women who still had residual invasive cancer in their breast following their surgery, approximately 30% of them had cancers that were now HER2 negative.
We performed a [...]